MarginScan™: Real-Time Surgical Margin Assessment

MarginScan™ enables rapid, non-destructive assessment of cancer margins during surgical excision. Using biospectral impedance and AI/ML, MarginScan detects and localizes residual cancer in seconds, without requiring frozen sectioning or dedicated pathology resources.

MarginScan supports healthy tissue–sparing surgery, improves workflow predictability, and can reduce recurrence—while preserving tissue for standard pathological analysis when desired.

MarginScan™ is manufactured by PHC Group, a division of PHC Holdings (TSE: 6523).

MarginScan laboratory instrument device

Skin Cancer

Mohs-like margin control without intraoperative histology.

Breast Surgery

Rapid assessment for breast-conserving surgery.

CPRIT Award

$3.7M grant for breast cancer application development.